
Browsing restrictions can be lifted for a fee.
0.98%
Vivosim labs, inc.
1.63%
Avg of Sector
0.63%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Vivosim labs, inc. (VIVS) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VIVS's short-term business performance and financial health. For the latest updates on VIVS's earnings releases, visit this page regularly.
According to the latest financial report, Vivosim labs, inc. (VIVS) reported an Operating Profit of -2.75M with an Operating Margin of -10,576.92% this period, representing a growth of 20.7% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Vivosim labs, inc. (VIVS) announced revenue of 26K, with a Year-Over-Year growth rate of 8.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Vivosim labs, inc. (VIVS) had total debt of 812K, with a debt ratio of 0.12. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Vivosim labs, inc. (VIVS) held Total Cash and Cash Equivalents of 4.43M, accounting for 0.64 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Vivosim labs, inc. (VIVS) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -10,576.92%%, and net margin of -10,350%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VIVS's profit trajectory and future growth potential.
According to the past four quarterly reports, Vivosim labs, inc. (VIVS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Vivosim labs, inc. (VIVS)'s Free Cash Flow (FCF) for the period is -2.27M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 26.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.